A randomized, double-blind, double-dummy, dose-ranging, active- and placebo-controlled study of single-dose oral rolapitant monotherapy for the prevention of postoperative nausea and vomiting (PONV).

Trial Profile

A randomized, double-blind, double-dummy, dose-ranging, active- and placebo-controlled study of single-dose oral rolapitant monotherapy for the prevention of postoperative nausea and vomiting (PONV).

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2013

At a glance

  • Drugs Ondansetron; Rolapitant
  • Indications Postoperative nausea and vomiting
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 23 Mar 2011 Primary endpoint 'Clinical-response-rate' has been met
    • 21 Oct 2009 Results have been presented at the 2009 Annual Meeting of the American Society of Anesthesiologists.
    • 21 Aug 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top